The location of a tumor fundamentally changes how hormones interact with immunity
For generations, medicine has treated testosterone as an adversary in the fight against cancer — a hormone to be suppressed, not preserved. But a Cleveland Clinic study published in 2026 quietly upends that certainty, at least within the confines of the skull: in glioblastoma, the brain's most lethal tumor, testosterone appears to be a guardian rather than a threat, holding the immune system steady against a disease that claims men's lives at a disproportionate rate. The finding invites a deeper question science is only beginning to ask — that where a cancer lives may matter as much as what it is.
- Glioblastoma is more common and more aggressive in men than in women, yet the hormonal reasons for that disparity have long eluded researchers.
- When testosterone is blocked in brain tumor models, stress hormones surge, immune cells are suppressed, and tumors accelerate — the precise opposite of what androgen-blocking achieves in lung, bladder, or skin cancers.
- The mechanism runs deeper than the tumor site: overactive microglia ignite brain inflammation that travels up the body's central stress axis, collapsing systemic immunity far beyond the brain itself.
- Male glioblastoma patients who received testosterone therapy alongside chemotherapy survived longer on average, lending human weight to the preclinical findings.
- The field now faces a significant recalibration — testosterone supplementation, long considered a contraindication in oncology, may need to be evaluated as a therapeutic tool for one of medicine's most resistant cancers.
For decades, oncology operated on a settled assumption: testosterone suppresses immune function and feeds cancer growth, so blocking it improves survival. That logic proved sound across lung, bladder, and melanoma cases. Then Cleveland Clinic's Justin Lathia and lead author Juyeun Lee turned their attention to glioblastoma — the most aggressive brain cancer, and one that strikes men more often and more severely than women — and found the assumption did not hold.
In their preclinical research, removing testosterone triggered a cascade no one had anticipated. Stress hormones spiked. Microglia, the brain's own immune sentinels, grew overactive and inflamed. That inflammation traveled up the hypothalamic-pituitary-adrenal axis — the body's central stress system — and suppressed immune function not just locally, but throughout the entire body. The tumor, freed from immune pressure, grew faster. Testosterone, it turned out, had been keeping that chain reaction in check.
The human data reinforced the picture. Registry analysis showed that male glioblastoma patients who received testosterone therapy alongside standard chemotherapy lived longer than those who did not. The team also observed that T cells — critical cancer-fighting immune cells — decline with age in men but not in women, a pattern that may reflect hormonal shifts over time.
Lathia frames the discovery as part of a larger evolution in cancer science — one that considers how tumors interact with the nervous and immune systems together, and how the location of a cancer fundamentally changes the rules. Where other cancers are harmed by androgens, the brain appears to depend on them for immune stability. The next step, he suggests, is testing testosterone supplementation as a genuine therapeutic option — a reversal of conventional thinking that could offer new ground in the fight against one of medicine's most formidable diseases.
For decades, researchers have operated from a straightforward assumption: testosterone, the primary male sex hormone, fuels cancer growth by dampening the immune system's ability to fight back. That logic held across multiple cancer types—lung, bladder, melanoma—where blocking androgens improved survival. But a new study from Cleveland Clinic's Justin Lathia and his team has found something unexpected in brain tumors. In glioblastoma, testosterone appears to do the opposite. It slows tumor progression. Blocking it makes things worse.
The finding matters because glioblastoma, the most aggressive form of brain cancer, strikes men harder and more often than women. The disease is more common in males and tends to progress faster. Scientists have long suspected sex chromosomes or sex hormones were responsible, but the mechanism remained unclear. Juyeun Lee, the study's lead author and now an assistant staff member at Cleveland Clinic's Florida facility, posed a direct question: In brain tumors specifically, do male hormones help or hurt the immune system's ability to fight back?
What the team discovered in their preclinical research was a cascade. Remove testosterone, and the body's stress hormones spike. Those stress hormones then suppress immune cells. Brain inflammation drives the whole process. The immune system weakens. The tumor grows. The culprit, they found, is microglia—the brain's resident immune cells. Testosterone normally keeps them in check. Without it, microglia become overactive, triggering inflammation that reaches deep into the hypothalamic-pituitary-adrenal axis, the body's central stress hub. That triggers a system-wide stress response that cripples immunity across the entire body, not just locally in the brain.
This is the opposite of what happens in cancers elsewhere. "In cancers outside the brain, blocking androgens can improve immunity," Lathia explains. "This is the opposite of what we discovered—and the implications are that this is more than just local tumor biology." The location of a tumor, in other words, fundamentally changes how hormones interact with the immune system. A hormone that suppresses cancer in the lungs might protect against it in the brain.
The team's observations aligned with human data. They analyzed cancer registry information and found that male glioblastoma patients who received testosterone therapy alongside standard chemotherapy lived longer on average than those who did not. They also noticed that T cells—the immune cells critical for fighting cancer—decline with age, but only in men. That age-related decline in male patients could stem from hormonal shifts, which prompted the researchers to examine testosterone's role more closely.
The implications are substantial. If testosterone actually protects against glioblastoma rather than promoting it, then the standard assumption that androgens should be blocked in cancer treatment needs revision—at least for brain tumors. Lathia sees the work as part of a broader shift in cancer science, one that looks beyond the tumor itself to how it interacts with the nervous system and immune system together. "We see so much potential for the future of glioblastoma treatment," he says. The next step, he suggests, is evaluating testosterone supplementation as a potential therapy, a reversal of conventional thinking that could open a new avenue for patients with one of the deadliest cancers.
Citações Notáveis
In cancers outside the brain, blocking androgens can improve immunity. This is the opposite of what we discovered—and the implications are that this is more than just local tumor biology.— Justin Lathia, Cleveland Clinic
We see so much potential for the future of glioblastoma treatment. Our ultimate assertion is that supplemental testosterone could be evaluated as a therapy.— Justin Lathia, Cleveland Clinic
A Conversa do Hearth Outra perspectiva sobre a história
So testosterone has always been the villain in cancer. Why would it suddenly be protective in the brain?
Because the brain is different. The immune cells there—microglia—respond to testosterone in a way that keeps inflammation in check. Without it, they go haywire and trigger a stress response that actually weakens immunity across the whole body.
That's counterintuitive. How did they figure this out?
They blocked testosterone in preclinical models and watched what happened. The chain reaction was clear: stress hormones spiked, immune cells got suppressed, tumors grew faster. Then they looked at real patient data and found men on testosterone therapy lived longer.
But doesn't that contradict what we know about testosterone and other cancers?
Exactly. In lung or bladder cancer, blocking testosterone helps. In glioblastoma, it hurts. The location matters. The brain's immune system works differently than the rest of the body.
So they're suggesting testosterone as a treatment now?
They're saying it should be evaluated as one. It's a complete reversal of the standard assumption, but the data points that way.